^
Association details:
| Biomarker: | SORT1 expression |
|---|---|
| Cancer: | Melanoma |
| Drug: | sudocetaxel zendusortide (TH 1902) (Tubulin polymerization promoter, Microtubule stabilizer, Sortilin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TH1902 in Patients With Advanced Solid Tumors
Excerpt:
...Histologically or cytologically confirmed TNBC, HR+ breast cancer, epithelial ovarian cancer, endometrial cancer, cutaneous melanoma, thyroid cancer, SCLC, prostate cancer or other cancer known to express SORT1 that is refractory or resistant to standard therapy (replaces inclusion criterion #3)....
Trial ID:
Source:
Title:
1313 - TH1902, a docetaxel peptide-drug conjugate, shows pre-clinical efficacy in several Sortilin-positive (SORT1+) cancers
Published date:
03/10/2021
Excerpt:
Pre-clinical in vivo studies were performed in human SORT1+ tumor xenografts grown in mice including TNBC (MDA-MB-231 and HCC-70), melanoma (SK-MEL-28), colorectal (HT-29) and pancreatic (PANC-1) cancer models. Mice were treated with either TH1902 or docetaxel by IV bolus injections...In all cases, TH1902 showed more potent inhibition than Docetaxel.
